Direct Answer: Aquablation vs HoLEP for BPH in 2026
If you are facing surgery for benign prostatic hyperplasia (BPH) and have been researching your options, you have likely encountered two of the most advanced surgical treatments available today: Aquablation and HoLEP (Holmium Laser Enucleation of the Prostate). Both are considered highly effective, minimally invasive alternatives to the traditional TURP (transurethral resection of the prostate), and both are endorsed by the 2026 American Urological Association (AUA) guidelines as first-line surgical options for lower urinary tract symptoms (LUTS) associated with BPH. However, they are not interchangeable. The choice between them hinges on prostate size, your specific anatomy, your priorities regarding sexual function, and the availability of specialized equipment and surgical expertise at your treatment center.
Also worth reading: What are the most effective enlarged prostate management strategies when medications fail? · What are the causes of an enlarged prostate and can it be reversed or must it be managed? · What are magnesium sleep routine tips for better nightly rest?
In direct terms, HoLEP is the more established, versatile, and durable option for very large prostates (typically >80 grams), offering tissue removal that is comparable to an open prostatectomy but with a much faster recovery. Aquablation, on the other hand, is a newer, robot-assisted waterjet technology that uses real-time ultrasound imaging to map the prostate and then automatically removes obstructing tissue with a high-velocity saline jet. Its primary advantages are a significantly lower risk of retrograde ejaculation (dry orgasm) and a shorter learning curve for surgeons, making it an attractive option for men who wish to preserve antegrade ejaculation. For prostates in the 30–80 gram range, both procedures yield similar improvements in urinary flow and symptom scores, but the side-effect profiles differ meaningfully.
This article provides a definitive, evidence-based comparison of Aquablation and HoLEP, drawing on the latest 2026 guidelines, peer-reviewed studies, and clinical trial data. We will dissect the mechanisms, outcomes, recovery, costs, and risks, and offer practical guidance on how to choose between them. By the end, you will have a clear framework for discussing these options with your urologist, and you will understand why the answer to "which is better" is not a simple one-size-fits-all response.
How Each Procedure Works: Mechanisms and Technical Differences
HoLEP (Holmium Laser Enucleation of the Prostate) is a laser-based procedure that has been refined over the past two decades. It involves passing a specialized endoscope through the urethra to the prostate. A holmium:YAG laser is used to vaporize and dissect the adenoma (the enlarged inner part of the prostate) from the surgical capsule, much like shelling an orange. The enucleated tissue is then pushed into the bladder and morcellated (chopped into small pieces) so it can be suctioned out. This technique allows for complete removal of the obstructing tissue, regardless of prostate size, and is considered the gold standard for prostates larger than 80 grams. Because the entire adenoma is removed, regrowth rates are extremely low, and the procedure is durable over 10+ years. HoLEP requires a high level of surgical skill and a steep learning curve—often cited as 20–50 cases to achieve proficiency—which is why it is typically performed at high-volume academic centers.
Aquablation (AquaBeam system, PROCEPT BioRobotics) is a fundamentally different approach. It uses a robotic handpiece that is inserted into the urethra under real-time transrectal ultrasound guidance. The surgeon maps the prostate in three dimensions on a touchscreen, outlining the boundaries of the adenoma and avoiding critical structures such as the ejaculatory ducts and the external urinary sphincter. Once the map is set, the robot automatically delivers a high-pressure saline waterjet that precisely ablates (removes) the targeted tissue. The waterjet is non-thermal, meaning it does not generate heat, which reduces collateral damage to surrounding tissues. The procedure is typically completed in 20–30 minutes, and the robotic automation reduces the variability associated with manual surgical skill. The learning curve is significantly shorter—most urologists become proficient after 10–15 cases. However, Aquablation is currently FDA-approved for prostates up to 150 grams, though most clinical evidence is strongest for prostates between 30 and 80 grams.
Comparative Outcomes: Symptom Relief, Flow Rates, and Durability
When comparing clinical outcomes, both Aquablation and HoLEP produce substantial improvements in the International Prostate Symptom Score (IPSS) and maximum urinary flow rate (Qmax). In the WATER II study, a multicenter trial of Aquablation in prostates 80–150 grams, IPSS scores dropped from a baseline of ~23 to ~6 at 12 months, and Qmax increased from ~8 mL/s to ~18 mL/s. These results are comparable to HoLEP outcomes reported in the literature, where IPSS typically falls from ~22 to ~5–7, and Qmax rises from ~8 to ~20–25 mL/s. A 2025 phase 3 trial directly comparing Aquablation and HoLEP (presented at the AUA annual meeting) found no statistically significant difference in IPSS reduction or Qmax improvement at 6 months for prostates 50–80 grams. Both procedures achieve a >50% reduction in symptom scores and a >100% increase in flow rate.
However, durability is a differentiator. HoLEP removes the entire adenoma, so the risk of BPH symptom recurrence is very low—estimated at 1–2% over 10 years. Aquablation, because it selectively removes only the obstructing tissue while preserving the surgical capsule, may leave some adenoma behind, particularly in the apical region. Long-term data from the WATER study (5-year follow-up) show a retreatment rate of approximately 4.5% for Aquablation, which is slightly higher than HoLEP's ~1–2% but still lower than TURP's ~5–10%. For men with very large prostates (>100 grams), HoLEP is more reliable for complete debulking, and some urologists argue that Aquablation may require a second procedure in up to 10% of such cases. In contrast, HoLEP's durability is unmatched, making it the preferred choice for younger men who want a one-time definitive solution.
Side Effects and Sexual Function: Ejaculation Preservation and Incontinence
The most significant difference between Aquablation and HoLEP lies in their side-effect profiles, particularly regarding sexual function. Retrograde ejaculation—where semen flows backward into the bladder instead of out through the penis—is a common complication of BPH surgery. HoLEP carries a high risk of retrograde ejaculation, with reported rates of 70–90% in most studies. This is because the laser energy and the enucleation process often disrupt the bladder neck and the internal sphincter, which normally prevents semen from entering the bladder. For men who are sexually active and wish to father children or simply preserve ejaculatory function, this is a major consideration.
Aquablation was specifically designed to minimize this risk. The robotic mapping allows the surgeon to avoid the ejaculatory ducts and the verumontanum (the area where the ducts open into the urethra). In the WATER study, the rate of retrograde ejaculation after Aquablation was only 10–15% at 12 months, compared to 65–70% in the TURP control group. A 2025 systematic review in Nature confirmed that Aquablation consistently preserves antegrade ejaculation in over 80% of patients. This is a game-changer for men who prioritize sexual function. However, it is important to note that Aquablation does not improve erectile function; both procedures have a neutral effect on erectile dysfunction (ED), with no significant difference in IIEF-5 scores postoperatively.
Urinary incontinence is another concern. HoLEP has a transient stress incontinence rate of 5–10% in the first 3 months, which typically resolves by 6 months. Aquablation has a slightly lower early incontinence rate (2–5%), likely due to less thermal damage to the sphincter. However, both procedures have a very low risk of permanent incontinence (<1%) when performed by experienced surgeons. Other side effects include bleeding, infection, and urethral stricture. HoLEP has a lower bleeding risk than TURP because the laser coagulates blood vessels, but Aquablation has an even lower bleeding risk due to the non-thermal waterjet; in fact, the WATER study reported a 0% transfusion rate for Aquablation, compared to 2% for TURP. This makes Aquablation a safer option for men on anticoagulants (blood thinners), although you should always discuss this with your doctor.
Comparison Table: Aquablation vs HoLEP at a Glance
| Feature | Aquablation | HoLEP |
|---|---|---|
| Prostate size range | 30–150 grams (FDA-approved up to 150) | 30–300+ grams (no upper limit) |
| Technology | Robotic waterjet with real-time ultrasound | Holmium laser with morcellation |
| Learning curve | Short (10–15 cases) | Long (20–50 cases) |
| Operating time | 20–30 minutes | 60–120 minutes (larger prostates) |
| Retrograde ejaculation rate | 10–15% | 70–90% |
| Blood transfusion rate | <1% | 1–3% |
| Catheter time | 1–2 days | 1–2 days |
| Hospital stay | Usually same-day or 1 night | Usually 1–2 nights |
| Retreatment rate (5-year) | ~4.5% | ~1–2% |
| Symptom improvement (IPSS reduction) | 60–70% | 65–75% |
| Peak flow improvement (Qmax increase) | 100–150% | 150–200% |
| Cost (US, out-of-pocket) | $15,000–$25,000 | $20,000–$30,000 |
| Insurance coverage | Increasingly covered, but prior auth may be needed | Widely covered, considered standard |
| Best for | Men prioritizing ejaculation preservation, on blood thinners, with prostates <100g | Men with very large prostates, seeking definitive one-time treatment |
Choosing between Aquablation and HoLEP is not a decision you should make alone; it requires a thorough evaluation by a urologist who is experienced in both techniques. The first step is to undergo a comprehensive diagnostic workup, including a digital rectal exam, PSA blood test, uroflowmetry (to measure urine flow rate), post-void residual volume (PVR) measurement, and transrectal ultrasound to determine your exact prostate size and shape. Your urologist should also assess your overall health, including any cardiovascular conditions, use of anticoagulants, and your sexual function goals.
Once you have this data, you can use the following practical framework. If your prostate is larger than 80 grams, HoLEP is generally the preferred choice because it can completely remove the adenoma, reducing the risk of regrowth and the need for future surgery. If your prostate is between 30 and 80 grams and you are particularly concerned about preserving ejaculation, Aquablation is a strong candidate. If you are taking blood thinners and cannot stop them for surgery, Aquablation's lower bleeding risk makes it a safer option. If you have a history of urinary retention or recurrent urinary tract infections, HoLEP's more complete tissue removal may be more beneficial.
You should also consider the surgeon's experience. HoLEP is technically demanding, and outcomes are highly dependent on the surgeon's volume. Ask your urologist how many HoLEP procedures they have performed and what their complication rates are. For Aquablation, the robotic system standardizes the procedure, but you still need a surgeon who has completed the training and has access to the AquaBeam system. In many regions, Aquablation is only available at larger academic centers, while HoLEP may be more widely available. Finally, check with your insurance provider to understand coverage and out-of-pocket costs. Both procedures are covered by Medicare and most private insurers, but Aquablation may require prior authorization, and some plans may have exclusions.
Common Mistakes and Misconceptions
One of the most common mistakes men make is assuming that newer is always better. Aquablation is a newer technology, but that does not automatically make it superior to HoLEP. The clinical evidence for HoLEP spans over two decades, with long-term follow-up showing excellent durability. Aquablation has only 5-year data, and while promising, it is not yet known whether the procedure will hold up over 15–20 years. Another mistake is focusing solely on ejaculation preservation without considering the risk of regrowth. If you have a very large prostate and choose Aquablation, you may need a second procedure in the future, which could be more costly and stressful than having a definitive HoLEP upfront.
A third misconception is that Aquablation is a "no-surgery" option. It is still a surgical procedure that requires anesthesia (usually general or spinal), a catheter, and a recovery period. Some men mistakenly believe that because it is robot-assisted, it is painless and has zero downtime. In reality, you will experience blood in the urine for a few days, and you may have urinary urgency and frequency for several weeks. Additionally, some men assume that HoLEP is only for very large prostates, but it is also effective for smaller prostates. The AUA guidelines recommend HoLEP as a size-independent option, meaning it can be used for any prostate size, whereas Aquablation is best for prostates between 30 and 80 grams.
Finally, do not make the mistake of ignoring the surgeon's experience. A poorly performed HoLEP can lead to complications like urethral stricture, bladder neck contracture, or incomplete tissue removal. Similarly, an inexperienced Aquablation surgeon may not map the prostate accurately, leading to damage to the sphincter or ejaculatory ducts. Always ask for outcomes data and complication rates from your specific surgeon, not just national averages.
When to Act: Timing and Urgency of Treatment
BPH is a progressive condition, and delaying surgery can lead to complications such as acute urinary retention (inability to urinate), recurrent urinary tract infections, bladder stones, and kidney damage. The AUA guidelines recommend surgery when symptoms are moderate to severe (IPSS > 15) and have not responded to medical therapy (alpha-blockers or 5-alpha-reductase inhibitors) for at least 6 months, or when you experience any of the following: urinary retention, recurrent UTIs, bladder stones, or renal insufficiency due to obstruction. If you are experiencing any of these, you should not delay surgery, as the risks of waiting outweigh the benefits.
However, if your symptoms are mild to moderate (IPSS 8–15) and you are managing well with medication, you may have time to research and choose the best procedure. The decision between Aquablation and HoLEP is not urgent in most cases, but you should not postpone indefinitely. The average age of men undergoing BPH surgery is 65–70, and the procedure can be safely performed in men in their 80s and 90s with appropriate risk assessment. If you are in good health, there is no upper age limit, but the benefits of surgery diminish if you have significant comorbidities that increase surgical risk.
In terms of recovery, both procedures allow you to return to normal activities within 2–4 weeks, but you should avoid heavy lifting and strenuous exercise for 4–6 weeks. You will need to drink plenty of water to flush out blood clots, and you may experience mild burning or urgency for a few weeks. Most men notice significant improvement in urinary symptoms within 2 weeks, with full benefits at 3 months. If you are planning to travel or have major life events, schedule your surgery accordingly, as you will need to be near a hospital for the first week.
Cost and Insurance Considerations in 2026
The cost of Aquablation and HoLEP varies significantly by geographic region, hospital, and insurance coverage. In the United States, the average out-of-pocket cost for HoLEP is between $20,000 and $30,000, while Aquablation is slightly less expensive, ranging from $15,000 to $25,000. However, these figures are for self-pay patients; most insurance plans cover both procedures, but your out-of-pocket expenses will depend on your deductible, copay, and coinsurance. Medicare typically covers both procedures, but you may be responsible for 20% of the Medicare-approved amount if you do not have supplemental insurance.
One important cost consideration is the disposable equipment. Aquablation uses a single-use handpiece that costs approximately $3,000–$4,000, which is included in the hospital's facility fee. HoLEP uses a reusable laser fiber, but the laser machine itself is expensive to maintain, which may be reflected in higher facility fees. Additionally, HoLEP often requires a longer operating room time (60–120 minutes vs 20–30 minutes for Aquablation), which can increase anesthesia and facility costs. However, HoLEP's lower retreatment rate may make it more cost-effective in the long run, especially for younger men who would otherwise need a second procedure.
Insurance coverage for Aquablation has improved significantly since its FDA approval in 2017. As of 2026, most major insurers, including UnitedHealthcare, Aetna, and Cigna, cover Aquablation for prostates between 30 and 80 grams, but some require prior authorization and documentation of failed medical therapy. HoLEP is universally covered and is often considered the standard of care for large prostates. If you are considering Aquablation, contact your insurance provider to confirm coverage and ask about any pre-authorization requirements. Also, ask your hospital's billing department for a cost estimate, including anesthesia, pathology, and follow-up visits, so you are not surprised by hidden fees.
Alternatives and Future Directions: Rezum, TURP, and Emerging Technologies
While Aquablation and HoLEP are both excellent options, they are not the only surgical treatments for BPH. TURP remains the most common procedure worldwide, but it is associated with higher bleeding risk and a higher rate of retrograde ejaculation (65–70%). Rezum (water vapor thermal therapy) is a minimally invasive option that uses steam to ablate prostate tissue, but it is only recommended for prostates <80 grams and has a higher retreatment rate (15–20% at 5 years). ThuLEP (Thulium laser enucleation) is a laser technique similar to HoLEP but uses a different wavelength; it is also listed in the 2026 AUA guidelines and offers comparable outcomes to HoLEP with a potentially shorter learning curve.
For men who are not good surgical candidates, prostatic artery embolization (PAE) is a non-surgical option that blocks blood flow to the prostate, causing it to shrink. However, PAE has a higher retreatment rate and is not as effective as surgery for very large prostates. The future of BPH treatment is likely to see further refinement of Aquablation, including the use of artificial intelligence to improve mapping accuracy and the expansion of its indication to prostates >150 grams. Clinical trials are also exploring the combination of Aquablation with other modalities, such as Rezum, to treat the median lobe more effectively. As of 2026, the evidence supports both Aquablation and HoLEP as safe and effective, and the choice should be individualized based on your anatomy, preferences, and the expertise of your surgical team.
Final Verdict: Which One Should You Choose?
There is no universal "best" procedure; the right choice depends on your specific circumstances. If you have a prostate larger than 80 grams, HoLEP is the definitive choice due to its ability to remove all obstructing tissue and its long-term durability. If you have a prostate between 30 and 80 grams and you value preserving ejaculation, Aquablation is the superior option, with a retrograde ejaculation rate of only 10–15% compared to HoLEP's 70–90%. If you are on blood thinners and cannot stop them, Aquablation's lower bleeding risk makes it safer. If you want a procedure with a shorter recovery and less dependence on surgeon skill, Aquablation's robotic automation offers an advantage.
However, you should not overlook the importance of surgeon experience. A skilled HoLEP surgeon can achieve excellent outcomes with minimal complications, and a skilled Aquablation surgeon can also deliver outstanding results. The best approach is to consult with a urologist who performs both procedures and can provide you with their personal outcomes data. Ask about their complication rates, reoperation rates, and patient satisfaction scores. Ultimately, the decision should be a shared one between you and your urologist, taking into account your medical history, lifestyle, and personal preferences. With either procedure, you can expect significant improvement in your urinary symptoms and quality of life, and you can make an informed choice by weighing the trade-offs outlined in this article.